Aegis Capital Corp. acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND). About...
Psyence Group Inc. (CSE: PSYG) reported that its subsidiary, Psyence Biomedical Ltd. issued four senior secured convertible notes to raise $10 million....
Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) ...
The company is a going concern, with a cumulative deficit of $4,132,349 as of August 31. The post PharmAla Biotech Reports Progress in Earnings appeared...
The firm managed to find adequate research funding over the year as sale talks emerged. The post Tryp Therapeutics Lowers Losses in 2023; Sees New Era...
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: PMBHF)released its audited financial statements in Canadian dollars for the year ended on August 31, 2023....
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development...
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and...
Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited. The post Tryp Therapeutics To Be Acquired by Exopharm appeared first...
Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin...